ClinicalTrials.gg
CompletedNCT01164579Updated Apr 22, 2015Results posted

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

A Phase 2 interventional study of Tasocitinib plus Methotrexate and Tofacitinib plus placebo methotrexate in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 40 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-22.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.

Enrollment
30th of 43
109 · median 170
Started
2010
with 4 others
Phase 2
12 of 43
2 open now
Registered
17th of 43
by date
Lead sponsor
25 of 43
Pfizer

Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 30th largest by enrollment, is one of 5 that started in 2010, is one of 12 in phase 2, and was the 17th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tofacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Early Rheumatoid Arthritis
  • Joint Structure
  • Magnetic Resonance Imaging
  • Janus Kinase (JAK) Inhibitor
  • Tasocitinib
  • Tofacitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with moderate to severe early rheumatoid arthritis (\< 2 years) who are methotrexate and biologic disease modifying antirheumatic drug naive.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating patients;
  • Patients with renal or hepatic impairment or other severe or progressing disease;
  • Patients with to magnetic resonance imaging with gadolinium contrast.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Tofacitinib (CP 690,550) 10 mg BID plus MTX

    Drug: Tasocitinib plus Methotrexate

  • Experimental
    Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX

    Drug: Tofacitinib plus placebo methotrexate

  • Active comparator
    Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk

    Drug: Placebo tofacitinib plus Methotrexate

Interventions

  • DrugTasocitinib plus Methotrexate

    Drug pages: Tofacitinib · Methotrexate

    Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months

  • DrugTofacitinib plus placebo methotrexate

    Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.

  • DrugPlacebo tofacitinib plus Methotrexate

    Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 3 in Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Wrist and Metacarpophalangeal (MCP) Synovitis

    Synovitis is defined as an area in the synovial compartment that shows above normal postgadolinium enhancement of a thickness greater than the width of the normal synovium. T1-weighted images were acquired before and after the administration of intravenous contrast agent containing gadolinium. Intravenous contrast was required to demonstrate enhancing synovitis. Synovitis was scored 0 to 3 in 3 wrist regions and in each of the first through fifth MCP joints. A score of 0 is normal, with no enhancement or enhancement up to the thickness of normal synovium, while scores of 1 to 3 (mild, moderate, severe) refer to increments of one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score ranges from a minimum of 0 to a maximum of 24. A negative value in synovitis change from Baseline score indicates an improvement.

    Time frame: Month 3

  2. Change From Baseline to Month 6 in OMERACT RAMRIS Wrist and MCP Bone Marrow Edema

    Bone edema was assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Bone edema was defined as a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone was scored separately; the scale was 0-3 based on the proportion of bone with edema, as follows 0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%. OMERACT RAMRIS total bone edema score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist was 75 (range 0-75). Increasing score=greater severity.

    Time frame: Month 6

Secondary outcomes

  1. Change From Baseline to Months 1, 6, and 12 in OMERACT RAMRIS Wrist and MCP Synovitis

    Synovitis is defined as an area in the synovial compartment that shows above normal postgadolinium enhancement of a thickness greater than the width of the normal synovium. T1-weighted images were acquired before and after the administration of intravenous contrast agent containing gadolinium. Intravenous contrast was required to demonstrate enhancing synovitis. Synovitis was scored 0 to 3 in 3 wrist regions and in each of the first through fifth MCP joints. A score of 0 is normal, with no enhancement or enhancement up to the thickness of normal synovium, while scores of 1 to 3 (mild, moderate, severe) refer to increments of one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score ranges from a minimum of 0 to a maximum of 24. A negative value in synovitis change from Baseline score indicates an improvement.

    Time frame: Months 1, 6, and 12

  2. Change From Baseline to Months 1, 3, and 12 in OMERACT RAMRIS Bone Marrow Edema in Wrist and MCP

    Bone edema was assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Bone edema was defined as a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone was scored separately; the scale was 0â€"3 based on the proportion of bone with edema, as follows 0: no edema; 1: 1â€"33% of bone edematous; 2: 34â€"66% of bone edematous; 3: 67â€"100%. OMERACT RAMRIS total bone edema score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist was 75 (range 0-75). Increasing score=greater severity.

    Time frame: Months 1, 3, and 12

  3. Change From Baseline to Months 1, 3, 6, and 12 in OMERACT RAMRIS Wrist and MCP Erosions

    Bone erosion assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Each site was scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. OMERACT RAMRIS total erosion score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist is 250 (range 0-250). Increasing score=greater severity.

    Time frame: Months 1, 3, 6, and 12

  4. Modified Total Sharp Score (mTSS) at Months 6 and 12

    Modified TSS is a measure of change in joint health. TSS is defined as joint space narrowing score (range 0 \[no narrowing\] to 168 \[high narrowing\]) plus (+) erosion score (range is from 0 \[no erosion\] to 280 \[high erosion\]). The modified TSS range is from 0 (no damage) to 448 (bad joint status). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

    Time frame: Months 6 and 12

  5. Change From Baseline to Months 6 and 12 in mTSS

    Modified TSS is a measure of change in joint health. TSS is defined as joint space narrowing score (range 0 \[no narrowing\] to 168 \[high narrowing\]) + erosion score (range is from 0 \[no erosion\] to 280 \[high erosion\]). The modified TSS range is from 0 (no damage) to 448 (bad joint status). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

    Time frame: Months 6 and 12

  6. Joint Space Narrowing (JSN) Scores at Months 6 and 12

    JSN score (a component of the modified TSS) is a measure of change in joint health. JSN score range is 0 (no narrowing) to 168 (high narrowing). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

    Time frame: Months 6 and 12

  7. Change From Baseline to Months 6 and 12 in JSN Scores

    JSN score (a component of the modified TSS) is a measure of change in joint health. JSN score range is 0 (no narrowing) to 168 (high narrowing). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

    Time frame: Months 6 and 12

  8. Erosion Scores at Months 6 and 12

    Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

    Time frame: Months 6 and 12

  9. Change From Baseline to Months 6 and 12 in Erosion Score

    Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

    Time frame: Months 6 and 12

  10. Percentage of Participants With an American College of Rheumatology (ACR) 20 Percent (%) Improvement (ACR20) Response

    ACR20 response: greater than or equal to (≥)20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Participant's Assessment of Pain; Participant's Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

    Time frame: Months 1, 2, 3, 6, 9, and 12

  11. Percentage of Participants With an ACR 50% Improvement (ACR50) Response

    ACR50 response: ≥ 50% improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Participant's Assessment of disease activity, 3) Paricipant's Assessment of Pain, 4) Participant's assessment of functional disability via a HAQ, and 5) CRP at each visit.

    Time frame: Months 1, 2, 3, 6, 9, and 12

  12. Percentage of Participants With an ACR 70% Improvement (ACR70) Response

    ACR70 response: ≥70% improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Participant's Assessment of Disease Activity, 3) Participant's Assessment of Pain, 4) Participant's Assessment of Functional Disability via a HAQ, and 5) CRP at each visit.

    Time frame: Months 1, 2, 3, 6, 9, and 12

  13. Disease Activity Score Based on 28-Joint Count and CRP (DAS28-3 [CRP])

    DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (≤)3.2 implied low disease activity and greater than (\>)3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (\<)2.6 = remission.

    Time frame: Baseline and Months 1, 2, 3, 6, 9, and 12

  14. Change From Baseline in DAS28-3 (CRP)

    DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity.

    Time frame: Months 1, 2, 3, 6, 9, and 12

  15. Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (DAS28-4 [ESR])

    DAS28-4 (ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (millimeters per hour \[mm/hour\]) and Participant Global Assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4; higher score=more disease activity. DAS28-4 (ESR) ≤3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.

    Time frame: Baseline and Months 1, 2, 3, 6, 9, and 12

  16. Change From Baseline in DAS28-4 (ESR)

    DAS28-4 (ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (millimeters per hour \[mm/hour\]) and Participant Global Assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4; higher score=more disease activity.

    Time frame: Months 1, 2, 3, 6, 9, and 12

  17. Percentage of Participants With DAS28-3 (CRP) Response (Good or Moderate Improvement)

    DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 categorical responses define a good (absolute: \<3.2 or \>1.2 improvement from baseline \[BL\]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: \>5.1 or \<0.6 change from BL).

    Time frame: Months 1, 2, 3, 6, 9, and 12

  18. Percentage of Participants With DAS28-3 (CRP) Score ≤3.2

    DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity.

    Time frame: Months 1, 2, 3, 6, 9, and 12

  19. Percentage of Participants With DAS28-3 (CRP) Score <2.6

    DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3(CRP) \<2.6 implied remission.

    Time frame: Months 1, 2, 3, 6, 9, and 12

  20. Percentage of Participants With DAS28-4 (ESR) Response (Good or Moderate Improvement)

    DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28 categorical responses define a good (absolute: \<3.2 or \>1.2 improvement from BL), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: \>5.1 or \<0.6 change from BL).

    Time frame: Months 1, 2, 3, 6, 9, and 12

  21. Percentage of Participants With DAS28-4 (ESR) ≤3.2

    DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity.

    Time frame: Months 1, 2, 3, 6, 9, and 12

  22. Percentage of Participants With DAS28-4 (ESR) <2.6

    DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28-4(ESR) \<2.6 implied remission.

    Time frame: Months 1, 2, 3, 6, 9, and 12

07

Results

Posted Apr 22, 2015

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib (CP-690,550) Plus Methotrexate (MTX)Tofacitinib (CP-690,550)Methotrexate
Started363637
Completed282721
Not completed8916
Withdrew: Lack of efficacy006
Withdrew: Lost to follow-up110
Withdrew: Withdrawal by subject253
Withdrew: Protocol violation012
Withdrew: Adverse event425
Withdrew: Reason not specified100

Outcome measures

PrimaryChange From Baseline to Month 3 in Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Wrist and Metacarpophalangeal (MCP) Synovitis

Synovitis is defined as an area in the synovial compartment that shows above normal postgadolinium enhancement of a thickness greater than the width of the normal synovium. T1-weighted images were acquired before and after the administration of intravenous contrast agent containing gadolinium. Intravenous contrast was required to demonstrate enhancing synovitis. Synovitis was scored 0 to 3 in 3 wrist regions and in each of the first through fifth MCP joints. A score of 0 is normal, with no enhancement or enhancement up to the thickness of normal synovium, while scores of 1 to 3 (mild, moderate, severe) refer to increments of one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score ranges from a minimum of 0 to a maximum of 24. A negative value in synovitis change from Baseline score indicates an improvement.

Time frame:
Month 3
Reported as:
Least squares mean · score on a scale
Change From Baseline to Month 3 in Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Wrist and Metacarpophalangeal (MCP) Synovitis
score on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Change From Baseline to Month 3 in Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Wrist and Metacarpophalangeal (MCP) Synovitis-0.80 ± 0.41-0.69 ± 0.40-0.17 ± 0.40
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.2696 (2-sided p-value; alpha equals (=) 0.10) · Difference in least squares (ls) mean: -0.63 · 90% CI -1.58 to 0.31
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.3561 (2-sided p-value; alpha=0.10) · Difference in ls mean: -0.52 · 90% CI -1.46 to 0.41
PrimaryChange From Baseline to Month 6 in OMERACT RAMRIS Wrist and MCP Bone Marrow Edema

Bone edema was assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Bone edema was defined as a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone was scored separately; the scale was 0-3 based on the proportion of bone with edema, as follows 0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%. OMERACT RAMRIS total bone edema score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist was 75 (range 0-75). Increasing score=greater severity.

Time frame:
Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Month 6 in OMERACT RAMRIS Wrist and MCP Bone Marrow Edema
score on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Change From Baseline to Month 6 in OMERACT RAMRIS Wrist and MCP Bone Marrow Edema-1.26 ± 0.41-1.45 ± 0.420.29 ± 0.42
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0089 (2-sided p-value; alpha= 0.10) · Difference in ls means: -1.55 · 90% CI -2.52 to -0.58
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0038 (2-sided p-value; alpha= 0.10) · Difference in ls means: -1.74 · 90% CI -2.72 to -0.76
SecondaryChange From Baseline to Months 1, 6, and 12 in OMERACT RAMRIS Wrist and MCP Synovitis

Synovitis is defined as an area in the synovial compartment that shows above normal postgadolinium enhancement of a thickness greater than the width of the normal synovium. T1-weighted images were acquired before and after the administration of intravenous contrast agent containing gadolinium. Intravenous contrast was required to demonstrate enhancing synovitis. Synovitis was scored 0 to 3 in 3 wrist regions and in each of the first through fifth MCP joints. A score of 0 is normal, with no enhancement or enhancement up to the thickness of normal synovium, while scores of 1 to 3 (mild, moderate, severe) refer to increments of one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score ranges from a minimum of 0 to a maximum of 24. A negative value in synovitis change from Baseline score indicates an improvement.

Time frame:
Months 1, 6, and 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Months 1, 6, and 12 in OMERACT RAMRIS Wrist and MCP Synovitis
score on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=28,31,35)-0.42 ± 0.42-0.34 ± 0.40-0.17 ± 0.38
Month 6 (n=33,29,28)-1.22 ± 0.40-1.29 ± 0.41-0.28 ± 0.42
Month 12 (n=29,26,21)-2.26 ± 0.41-1.16 ± 0.43-0.66 ± 0.46
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.6576 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.25 · 90% CI -1.19 to 0.69
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.7565 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.17 · 90% CI -1.09 to 0.74
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.1038 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.94 · 90% CI -1.89 to 0.01
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0868 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.01 · 90% CI -1.98 to -0.04
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0103 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.60 · 90% CI -2.62 to -0.58
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.4350 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.49 · 90% CI -1.53 to 0.55
SecondaryChange From Baseline to Months 1, 3, and 12 in OMERACT RAMRIS Bone Marrow Edema in Wrist and MCP

Bone edema was assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Bone edema was defined as a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone was scored separately; the scale was 0â€"3 based on the proportion of bone with edema, as follows 0: no edema; 1: 1â€"33% of bone edematous; 2: 34â€"66% of bone edematous; 3: 67â€"100%. OMERACT RAMRIS total bone edema score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist was 75 (range 0-75). Increasing score=greater severity.

Time frame:
Months 1, 3, and 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Months 1, 3, and 12 in OMERACT RAMRIS Bone Marrow Edema in Wrist and MCP
score on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=28,31,35)-0.29 ± 0.430.19 ± 0.410.11 ± 0.39
Month 3 (n=30,32,31)-0.77 ± 0.42-0.86 ± 0.410.47 ± 0.41
Month 12 (n=29,26,21)-1.52 ± 0.42-1.70 ± 0.430.59 ± 0.46
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.4890 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.40 · 90% CI -1.36 to 0.56
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.8817 (2-sided p-value; alpha=0.10) · Difference in ls means: 0.08 · 90% CI -0.85 to 1.02
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0351 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.24 · 90% CI -2.21 to -0.27
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0231 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.32 · 90% CI -2.28 to -0.37
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0008 (2-sided p-value; alpha=0.10) · Difference in ls means: -2.10 · 90% CI -3.13 to -1.08
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0003 (2-sided p-value; alpha=0.10) · Difference in ls means: -2.29 · 90% CI -3.32 to -1.25
SecondaryChange From Baseline to Months 1, 3, 6, and 12 in OMERACT RAMRIS Wrist and MCP Erosions

Bone erosion assessed at 25 anatomic locations: 15 in 1 wrist and 10 in attached hand. Each site was scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. OMERACT RAMRIS total erosion score for hands/wrists was sum of the individual scores for each location. Thus the maximum score per hand/wrist is 250 (range 0-250). Increasing score=greater severity.

Time frame:
Months 1, 3, 6, and 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Months 1, 3, 6, and 12 in OMERACT RAMRIS Wrist and MCP Erosions
score on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=28,31,35)-0.12 ± 0.250.27 ± 0.250.27 ± 0.24
Month 3 (n=30,32,31)-0.12 ± 0.250.36 ± 0.240.44 ± 0.25
Month 6 (n=33,29,28)-0.06 ± 0.25-0.02 ± 0.250.65 ± 0.25
Month 12 (n=29,26,21)-0.11 ± 0.25-0.08 ± 0.251.18 ± 0.26
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.2689 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.39 · 90% CI -0.96 to 0.19
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.9935 (2-sided p-value; alpha=0.10) · Difference in ls means: 0 · 90% CI -0.58 to 0.57
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.1086 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.57 · 90% CI -1.15 to 0.01
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.8092 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.08 · 90% CI -0.66 to 0.49
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0463 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.71 · 90% CI -1.29 to -0.12
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0624 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.67 · 90% CI -1.25 to -0.08
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0005 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.29 · 90% CI -1.90 to -0.69
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0008 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.26 · 90% CI -1.87 to -0.65
SecondaryModified Total Sharp Score (mTSS) at Months 6 and 12

Modified TSS is a measure of change in joint health. TSS is defined as joint space narrowing score (range 0 \[no narrowing\] to 168 \[high narrowing\]) plus (+) erosion score (range is from 0 \[no erosion\] to 280 \[high erosion\]). The modified TSS range is from 0 (no damage) to 448 (bad joint status). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

Time frame:
Months 6 and 12
Reported as:
Least squares mean · score on a scale
Modified Total Sharp Score (mTSS) at Months 6 and 12
score on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 6 (n=29,27,28)11.28 ± 0.5010.70 ± 0.5111.77 ± 0.52
Month 12 (n=26,25,22)11.70 ± 0.5110.69 ± 0.5212.21 ± 0.54
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.5019 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.48 · 90% CI -1.68 to 0.71
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.1462 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.07 · 90% CI -2.28 to 0.14
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.4900 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.51 · 90% CI -1.74 to 0.72
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0459 · Difference in ls means: -1.51 · 90% CI -2.76 to -0.27
SecondaryChange From Baseline to Months 6 and 12 in mTSS

Modified TSS is a measure of change in joint health. TSS is defined as joint space narrowing score (range 0 \[no narrowing\] to 168 \[high narrowing\]) + erosion score (range is from 0 \[no erosion\] to 280 \[high erosion\]). The modified TSS range is from 0 (no damage) to 448 (bad joint status). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

Time frame:
Months 6 and 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline to Months 6 and 12 in mTSS
scores on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 6 (n=29,27,28)0.44 ± 0.50-0.14 ± 0.510.93 ± 0.52
Month 12 (n=26,25,22)0.85 ± 0.51-0.15 ± 0.521.36 ± 0.54
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.5019 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.48 · 90% CI -1.68 to 0.71
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.1462 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.07 · 90% CI -2.28 to 0.14
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.4900 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.51 · 90% CI -1.74 to 0.72
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0459 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.51 · 90% CI -2.76 to -0.27
SecondaryJoint Space Narrowing (JSN) Scores at Months 6 and 12

JSN score (a component of the modified TSS) is a measure of change in joint health. JSN score range is 0 (no narrowing) to 168 (high narrowing). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

Time frame:
Months 6 and 12
Reported as:
Least squares mean · score on a scale
Joint Space Narrowing (JSN) Scores at Months 6 and 12
score on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 6 (n=29,27,28)5.45 ± 0.345.11 ± 0.355.52 ± 0.36
Month 12 (n=26,25,22)5.59 ± 0.355.05 ± 0.365.88 ± 0.37
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.8959 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.07 · 90% CI -0.89 to 0.76
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.4193 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.41 · 90% CI -1.25 to 0.43
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.5764 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.29 · 90% CI -1.13 to 0.56
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.1101 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.83 · 90% CI -1.69 to 0.02
SecondaryChange From Baseline to Months 6 and 12 in JSN Scores

JSN score (a component of the modified TSS) is a measure of change in joint health. JSN score range is 0 (no narrowing) to 168 (high narrowing). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

Time frame:
Months 6 and 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline to Months 6 and 12 in JSN Scores
scores on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 6 (n=29,27,28)0.29 ± 0.34-0.06 ± 0.350.35 ± 0.36
Month 12 (n=26,25,22)0.43 ± 0.35-0.12 ± 0.360.71 ± 0.37
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.8959 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.07 · 90% CI -0.89 to 0.76
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.4193 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.41 · 90% CI -1.25 to 0.43
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.5764 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.29 · 90% CI -1.13 to 0.56
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.1101 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.83 · 90% CI -1.69 to 0.02
SecondaryErosion Scores at Months 6 and 12

Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

Time frame:
Months 6 and 12
Reported as:
Least squares mean · scores on a scale
Erosion Scores at Months 6 and 12
scores on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 6 (n=29,27,28)5.84 ± 0.245.59 ± 0.256.26 ± 0.25
Month 12 (n=26,25,22)6.10 ± 0.255.64 ± 0.266.33 ± 0.27
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.2351 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.42 · 90% CI -1.00 to 0.16
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0631 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.67 · 90% CI -1.27 to -0.08
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.5369 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.23 · 90% CI -0.83 to 0.38
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0620 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.69 · 90% CI -1.31 to -0.08
SecondaryChange From Baseline to Months 6 and 12 in Erosion Score

Erosion score (a component of the modified TSS) is a measure of change in joint health. Erosion score range is from 0 (no erosion) to 280 (high erosion). Increase from baseline represents disease progression and / or joint worsening; no change represents halting of disease progression; a decrease represents improvement.

Time frame:
Months 6 and 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline to Months 6 and 12 in Erosion Score
scores on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 6 (n=29,27,28)0.16 ± 0.24-0.10 ± 0.250.58 ± 0.25
Month 12 (n=26,25,22)0.42 ± 0.25-0.05 ± 0.260.65 ± 0.27
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.2351 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.42 · 90% CI -1.00 to 0.16
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0631 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.67 · 90% CI -1.27 to -0.08
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.5369 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.23 · 90% CI -0.83 to 0.38
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0620 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.69 · 90% CI -1.31 to -0.08
SecondaryPercentage of Participants With an American College of Rheumatology (ACR) 20 Percent (%) Improvement (ACR20) Response

ACR20 response: greater than or equal to (≥)20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Participant's Assessment of Pain; Participant's Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 20 Percent (%) Improvement (ACR20) Response
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=35,35,37)42.8657.1429.73
Month 2 (n=35,36,37)68.5761.1140.54
Month 3 (n=35,36,37)77.1461.1148.65
Month 6 (n=35,36,37)74.2966.6745.95
Month 9 (n=35,36,37)71.4358.3343.24
Month 12 (n=35,36,37)71.4361.1143.24
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.2430 · Mean difference (final values): 13.12 · 90% CI -5.36 to 31.62
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0147 · Mean difference (final values): 27.41 · 90% CI 8.91 to 45.90
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0127 · Mean difference (final values): 28.03 · 90% CI 9.51 to 46.54
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0724 · Mean difference (final values): 20.57 · 90% CI 1.73 to 39.41
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0086 · Mean difference (final values): 28.49 · 90% CI 10.63 to 46.35
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.2808 · Mean difference (final values): 12.46 · 90% CI -6.54 to 31.47
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0115 · Mean difference (final values): 28.18 · 90% CI 9.81 to 46.55
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1921 · Mean difference (final values): 15.09 · 90% CI -3.94 to 34.12
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0115 · Mean difference (final values): 28.18 · 90% CI 9.81 to 46.55
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1203 · Mean difference (final values): 17.86 · 90% CI -1.05 to 36.79
SecondaryPercentage of Participants With an ACR 50% Improvement (ACR50) Response

ACR50 response: ≥ 50% improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Participant's Assessment of disease activity, 3) Paricipant's Assessment of Pain, 4) Participant's assessment of functional disability via a HAQ, and 5) CRP at each visit.

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 50% Improvement (ACR50) Response
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=35,35,37)22.8622.862.70
Month 2 (n=35,36,37)45.7133.3316.22
Month 3 (n=35,36,37)48.5750.0024.32
Month 6 (n=35,36,37)57.1447.2221.62
Month 9 (n=35,36,37)57.1444.4429.73
Month 12 (n=35,36,37)57.1444.4429.73
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0078 · Mean difference (final values): 20.15 · 90% CI 7.68 to 32.62
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0078 · Mean difference (final values): 20.15 · 90% CI 7.68 to 32.62
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0044 · Mean difference (final values): 29.49 · 90% CI 12.43 to 46.56
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0845 · Mean difference (final values): 17.11 · 90% CI 0.79 to 33.43
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0275 · Mean difference (final values): 24.24 · 90% CI 6.14 to 42.35
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0186 · Mean difference (final values): 25.67 · 90% CI 7.71 to 43.63
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0009 · Mean difference (final values): 35.52 · 90% CI 17.82 to 53.22
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0169 · Mean difference (final values): 25.60 · 90% CI 7.95 to 43.24
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0147 · Mean difference (final values): 27.41 · 90% CI 8.91 to 45.90
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1882 · Mean difference (final values): 14.71 · 90% CI -3.68 to 33.11
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0147 · Mean difference (final values): 27.41 · 90% CI 8.91 to 45.90
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1882 · Mean difference (final values): 14.71 · 90% CI -3.68 to 33.11
SecondaryPercentage of Participants With an ACR 70% Improvement (ACR70) Response

ACR70 response: ≥70% improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Participant's Assessment of Disease Activity, 3) Participant's Assessment of Pain, 4) Participant's Assessment of Functional Disability via a HAQ, and 5) CRP at each visit.

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 70% Improvement (ACR70) Response
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=35,35,37)8.572.860.00
Month 2 (n=35,36,37)31.4322.225.41
Month 3 (n=35,36,37)25.7127.7810.81
Month 6 (n=35,36,37)34.2930.5621.62
Month 9 (n=35,36,37)31.4333.3318.92
Month 12 (n=35,36,37)22.8633.3321.62
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0700 · Mean difference (final values): 8.57 · 90% CI 0.78 to 16.35
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.3102 · Mean difference (final values): 2.85 · 90% CI -1.77 to 7.48
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0027 · Mean difference (final values): 26.02 · 90% CI 11.73 to 40.30
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0324 · Mean difference (final values): 16.81 · 90% CI 3.88 to 29.75
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0969 · Mean difference (final values): 14.90 · 90% CI 0.13 to 29.67
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0606 · Mean difference (final values): 16.96 · 90% CI 2.09 to 31.84
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.2276 · Mean difference (net): 12.66 · 90% CI -4.60 to 29.93
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.3827 · Mean difference (final values): 8.93 · 90% CI -7.90 to 25.76
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.2177 · Mean difference (final values): 12.50 · 90% CI -4.18 to 29.20
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1558 · Mean difference (final values): 14.41 · 90% CI -2.29 to 31.12
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.8997 · Mean difference (final values): 1.23 · 90% CI -14.89 to 17.36
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.2587 · Mean difference (final values): 11.71 · 90% CI -5.34 to 28.76
SecondaryDisease Activity Score Based on 28-Joint Count and CRP (DAS28-3 [CRP])

DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (≤)3.2 implied low disease activity and greater than (\>)3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (\<)2.6 = remission.

Time frame:
Baseline and Months 1, 2, 3, 6, 9, and 12
Reported as:
Mean · score on a scale
Disease Activity Score Based on 28-Joint Count and CRP (DAS28-3 [CRP])
score on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Baseline (n=36,36,37)5.14 ± 0.965.48 ± 0.785.36 ± 0.80
Month 1 (n=33,35,37)3.71 ± 1.154.03 ± 0.914.65 ± 1.07
Month 2 (n=33,33,32)2.99 ± 1.173.52 ± 1.154.21 ± 1.31
Month 3 (n=33,33,31)3.06 ± 1.023.46 ± 1.093.87 ± 1.43
Month 6 (n=31,29,29)2.74 ± 1.152.75 ± 0.953.92 ± 1.49
Month 9 (n=30,28,24)2.37 ± 0.982.85 ± 0.903.58 ± 1.63
Month 12 (n=27,26,20)2.49 ± 1.022.68 ± 1.053.58 ± 1.40
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -0.22 · 90% CI -0.56 to 0.13
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): 0.12 · 90% CI -0.19 to 0.43
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -0.94 · 90% CI -1.38 to -0.50
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.62 · 90% CI -1.01 to -0.22
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -1.21 · 90% CI -1.73 to -0.70
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.69 · 90% CI -1.20 to -0.18
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -0.81 · 90% CI -1.33 to -0.29
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.41 · 90% CI -0.94 to 0.12
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -1.18 · 90% CI -1.75 to -0.61
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -1.18 · 90% CI -1.73 to -0.63
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -1.21 · 90% CI -1.81 to -0.61
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.73 · 90% CI -1.33 to -0.13
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -1.10 · 90% CI -1.69 to -0.51
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.90 · 90% CI -1.51 to -0.29
SecondaryChange From Baseline in DAS28-3 (CRP)

DAS28-3 (CRP) was calculated from the swollen joint count and tender joint count using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity.

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in DAS28-3 (CRP)
scores on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=33,35,37)-1.61 ± 0.19-1.40 ± 0.18-0.73 ± 0.18
Month 2 (n=33,33,32)-2.32 ± 0.19-1.88 ± 0.19-1.24 ± 0.19
Month 3 (n=33,33,31)-2.25 ± 0.19-1.96 ± 0.19-1.57 ± 0.19
Month 6 (n=31,29,29)-2.54 ± 0.19-2.55 ± 0.20-1.52 ± 0.19
Month 9 (n=30,28,24)-2.92 ± 0.20-2.43 ± 0.20-1.76 ± 0.21
Month 12 (n=27,26,20)-2.78 ± 0.20-2.61 ± 0.20-1.77 ± 0.22
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0010 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.88 · 90% CI -1.31 to -0.45
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0102 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.67 · 90% CI -1.10 to -0.24
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = <0.0001 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.08 · 90% CI -1.52 to -0.64
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0175 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.64 · 90% CI -1.08 to -0.20
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0125 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.68 · 90% CI -1.13 to -0.23
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.1457 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.39 · 90% CI -0.84 to 0.05
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0003 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.02 · 90% CI -1.48 to -0.57
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0002 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.03 · 90% CI -1.49 to -0.58
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = <0.0001 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.16 · 90% CI -1.63 to -0.69
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0196 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.67 · 90% CI -1.14 to -0.20
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0007 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.01 · 90% CI -1.50 to -0.52
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0049 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.84 · 90% CI -1.32 to -0.35
SecondaryDisease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (DAS28-4 [ESR])

DAS28-4 (ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (millimeters per hour \[mm/hour\]) and Participant Global Assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4; higher score=more disease activity. DAS28-4 (ESR) ≤3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.

Time frame:
Baseline and Months 1, 2, 3, 6, 9, and 12
Reported as:
Mean · scores on a scale
Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (DAS28-4 [ESR])
scores on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Baseline (n=36,36,37)6.25 ± 0.946.50 ± 0.756.44 ± 0.78
Month 1 (n=34,35,37)4.60 ± 1.374.93 ± 1.125.51 ± 1.09
Month 2 (n=32,33,31)3.77 ± 1.344.36 ± 1.405.05 ± 1.26
Month 3 (n=33,33,31)3.66 ± 1.164.12 ± 1.314.63 ± 1.63
Month 6 (n=30,29,28)3.32 ± 1.453.51 ± 1.204.75 ± 1.76
Month 9 (n=30,28,24)3.06 ± 1.273.58 ± 1.104.17 ± 1.91
Month 12 (n=27,26,20)3.02 ± 1.223.47 ± 1.364.13 ± 1.76
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -0.19 · 90% CI -0.53 to 0.15
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): 0.06 · 90% CI -0.24 to 0.36
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -0.91 · 90% CI -1.40 to -0.42
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.58 · 90% CI -1.01 to -0.14
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -1.28 · 90% CI -1.82 to -0.73
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.69 · 90% CI -1.25 to -0.13
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -0.96 · 90% CI -1.55 to -0.38
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.51 · 90% CI -1.12 to 0.11
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -1.43 · 90% CI -2.13 to -0.72
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -1.24 · 90% CI -1.91 to -0.57
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -1.11 · 90% CI -1.84 to -0.39
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.59 · 90% CI -1.30 to 0.13
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Mean difference (final values): -1.11 · 90% CI -1.84 to -0.39
  • Tofacitinib (CP-690,550) vs Methotrexate · Mean difference (final values): -0.66 · 90% CI -1.43 to 0.11
SecondaryChange From Baseline in DAS28-4 (ESR)

DAS28-4 (ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (millimeters per hour \[mm/hour\]) and Participant Global Assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4; higher score=more disease activity.

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline in DAS28-4 (ESR)
scores on a scaleTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=34,35,37)-1.77 ± 0.21-1.57 ± 0.21-0.94 ± 0.20
Month 2 (n=32,33,31)-2.59 ± 0.22-2.08 ± 0.21-1.41 ± 0.21
Month 3 (n=33,33,31)-2.69 ± 0.21-2.35 ± 0.21-1.80 ± 0.21
Month 6 (n=30,29,28)-3.02 ± 0.22-2.81 ± 0.22-1.73 ± 0.22
Month 9 (n=30,28,24)-3.29 ± 0.22-2.72 ± 0.22-2.14 ± 0.23
Month 12 (n=27,26,20)-3.31 ± 0.22-2.84 ± 0.22-2.18 ± 0.24
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0046 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.84 · 90% CI -1.32 to -0.35
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0303 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.63 · 90% CI -1.11 to -0.15
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0001 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.18 · 90% CI -1.69 to -0.68
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0255 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.67 · 90% CI -1.17 to -0.18
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0035 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.89 · 90% CI -1.39 to -0.39
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0683 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.55 · 90% CI -1.05 to -0.05
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = <0.0001 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.29 · 90% CI -1.81 to -0.78
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0006 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.08 · 90% CI -1.59 to -0.56
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0004 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.15 · 90% CI -1.67 to -0.62
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0706 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.58 · 90% CI -1.10 to -0.05
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · mixed model repeated measures analysis · p = 0.0008 (2-sided p-value; alpha=0.10) · Difference in ls means: -1.13 · 90% CI -1.67 to -0.58
  • Tofacitinib (CP-690,550) vs Methotrexate · mixed model repeated measures analysis · p = 0.0466 (2-sided p-value; alpha=0.10) · Difference in ls means: -0.66 · 90% CI -1.21 to -0.12
SecondaryPercentage of Participants With DAS28-3 (CRP) Response (Good or Moderate Improvement)

DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 categorical responses define a good (absolute: \<3.2 or \>1.2 improvement from baseline \[BL\]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: \>5.1 or \<0.6 change from BL).

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-3 (CRP) Response (Good or Moderate Improvement)
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=33,35,37)75.7671.4343.24
Month 2 (n=34,36,37)91.1880.5656.76
Month 3 (n=34,36,37)91.1877.7856.76
Month 6 (n=34,36,37)88.2477.7854.05
Month 9 (n=34,36,37)79.4169.4445.95
Month 12 (n=34,36,37)82.3572.2245.95
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0032 (2-sided p-value; alpha=0.10) · Mean difference (final values): 32.51 · 90% CI 14.34 to 50.68
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0115 (2-sided p-value; alpha=0.10) · Mean difference (final values): 28.18 · 90% CI 9.81 to 46.55
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0002 (2-sided p-value; alpha=0.10) · Mean difference (final values): 34.41 · 90% CI 18.81 to 50.02
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0231 (2-sided p-value; alpha=0.10) · Mean difference (final values): 23.79 · 90% CI 6.55 to 41.03
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0002 (2-sided p-value; alpha=0.10) · Mean difference (final values): 34.41 · 90% CI 18.81 to 50.02
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0493 (2-sided p-value; alpha=0.10) · Mean difference (final values): 21.02 · 90% CI 3.43 to 38.61
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0005 (2-sided p-value; alpha=0.10) · Mean difference (final values): 34.18 · 90% CI 17.92 to 50.43
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0270 (2-sided p-value; alpha=0.10) · Mean difference (final values): 23.72 · 90% CI 6.07 to 41.37
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0018 (2-sided p-value; alpha=0.10) · Mean difference (final values): 33.46 · 90% CI 15.80 to 51.12
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0363 (2-sided p-value; alpha=0.10) · Mean difference (final values): 23.49 · 90% CI 5.02 to 41.96
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0005 (2-sided p-value; alpha=0.10) · Mean difference (final values): 36.40 · 90% CI 19.16 to 53.64
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0177 (2-sided p-value; alpha=0.10) · Mean difference (final values): 26.27 · 90% CI 8.04 to 44.50
SecondaryPercentage of Participants With DAS28-3 (CRP) Score ≤3.2

DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity.

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-3 (CRP) Score ≤3.2
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=33,35,37)33.3317.1410.81
Month 2 (n=34,36,37)50.0036.1121.62
Month 3 (n=34,36,37)50.0041.6721.62
Month 6 (n=34,36,37)61.7655.5627.03
Month 9 (n=34,36,37)64.7158.3329.33
Month 12 (n=34,36,37)61.7650.0027.03
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0197 (2-sided p-value; alpha=0.10) · Mean difference (final values): 22.52 · 90% CI 6.62 to 38.42
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.4379 (2-sided p-value; alpha=0.10) · Mean difference (final values): 6.33 · 90% CI -7.09 to 19.76
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0093 (2-sided p-value; alpha=0.10) · Mean difference (final values): 28.37 · 90% CI 10.40 to 46.34
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1669 (2-sided p-value; alpha=0.10) · Mean difference (final values): 14.48 · 90% CI -2.75 to 31.73
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0093 (2-sided p-value; alpha=0.10) · Mean difference (final values): 28.37 · 90% CI 10.40 to 46.34
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0596 (2-sided p-value; alpha=0.10) · Mean difference (final values): 20.04 · 90% CI 2.53 to 37.55
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0017 (2-sided p-value; alpha=0.10) · Mean difference (final values): 34.73 · 90% CI 16.51 to 52.96
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0097 (2-sided p-value; alpha=0.10) · Mean difference (final values): 28.52 · 90% CI 10.36 to 46.69
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0016 (2-sided p-value; alpha=0.10) · Mean difference (final values): 34.97 · 90% CI 16.68 to 53.26
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0102 (2-sided p-value; alpha=0.10) · Mean difference (final values): 28.60 · 90% CI 10.28 to 46.91
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0017 (2-sided p-value; alpha=0.10) · Mean difference (final values): 34.73 · 90% CI 16.51 to 52.96
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0381 (2-sided p-value; alpha=0.10) · Mean difference (final values): 22.97 · 90% CI 4.74 to 41.19
SecondaryPercentage of Participants With DAS28-3 (CRP) Score <2.6

DAS28-3(CRP) was calculated from the swollen joint count and tender joint count using 28-joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3(CRP) \<2.6 implied remission.

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-3 (CRP) Score <2.6
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=33,35,37)18.185.715.41
Month 2 (n=34,36,37)35.2916.678.11
Month 3 (n=34,36,37)32.3522.2213.51
Month 6 (n=34,36,37)47.0633.3316.22
Month 9 (n=34,36,37)50.0038.8918.92
Month 12 (n=34,36,37)47.0633.3313.51
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0959 (2-sided p-value; alpha=0.10) · Mean difference (final values): 12.77 · 90% CI 0.15 to 25.40
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.9544 (2-sided p-value; alpha=0.10) · Mean difference (final values): 0.30 · 90% CI -8.58 to 9.19
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0036 (2-sided p-value; alpha=0.10) · Mean difference (final values): 27.18 · 90% CI 11.81 to 42.55
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.2640 (2-sided p-value; alpha=0.10) · Mean difference (final values): 8.55 · 90% CI -4.04 to 21.16
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0544 (2-sided p-value; alpha=0.10) · Mean difference (final values): 18.83 · 90% CI 2.72 to 34.95
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.3290 (2-sided p-value; alpha=0.10) · Mean difference (final values): 8.70 · 90% CI -5.96 to 23.38
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0032 (2-sided p-value; alpha=0.10) · Mean difference (final values): 30.84 · 90% CI 13.59 to 48.09
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0845 (2-sided p-value; alpha=0.10) · Mean difference (final values): 17.11 · 90% CI 0.79 to 33.43
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0037 (2-sided p-value; alpha=0.10) · Mean difference (final values): 31.08 · 90% CI 13.44 to 48.72
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0540 (2-sided p-value; alpha=0.10) · Mean difference (final values): 19.96 · 90% CI 2.91 to 37.02
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0010 (2-sided p-value; alpha=0.10) · Mean difference (final values): 33.54 · 90% CI 16.70 to 50.39
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0401 (2-sided p-value; alpha=0.10) · Mean difference (final values): 19.81 · 90% CI 3.92 to 35.71
SecondaryPercentage of Participants With DAS28-4 (ESR) Response (Good or Moderate Improvement)

DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28 categorical responses define a good (absolute: \<3.2 or \>1.2 improvement from BL), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: \>5.1 or \<0.6 change from BL).

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-4 (ESR) Response (Good or Moderate Improvement)
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=34,35,37)67.6562.8629.73
Month 2 (n=32,33,31)85.2969.4459.46
Month 3 (n=33,33,31)91.1869.4451.35
Month 6 (n=30,29,28)85.2977.7851.35
Month 9 (n=30,28,24)82.3572.2245.95
Month 12 (n=27,26,20)79.4169.4445.95
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0005 (2-sided p-value; alpha=0.10) · Mean difference (final values): 37.91 · 90% CI 19.83 to 55.99
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0028 (2-sided p-value; alpha=0.10) · Mean difference (final values): 33.12 · 90% CI 14.87 to 51.38
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0105 (2-sided p-value; alpha=0.10) · Mean difference (final values): 25.83 · 90% CI 9.21 to 42.45
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.3700 (2-sided p-value; alpha=0.10) · Mean difference (final values): 9.98 · 90% CI -8.33 to 28.30
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = <0.0001 (2-sided p-value; alpha=0.10) · Mean difference (final values): 39.82 · 90% CI 24.11 to 55.53
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1076 (2-sided p-value; alpha=0.10) · Mean difference (final values): 18.09 · 90% CI -0.40 to 36.59
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0008 (2-sided p-value; alpha=0.10) · Mean difference (final values): 33.94 · 90% CI 17.13 to 50.75
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0139 (2-sided p-value; alpha=0.10) · Mean difference (final values): 26.42 · 90% CI 8.74 to 44.10
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0005 (2-sided p-value; alpha=0.10) · Mean difference (final values): 36.40 · 90% CI 19.16 to 53.64
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0177 · Mean difference (final values): 26.27 · 90% CI 8.04 to 44.50
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0018 (2-sided p-value; alpha=0.10) · Mean difference (final values): 33.46 · 90% CI 15.80 to 51.12
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0363 (2-sided p-value; alpha=0.10) · Mean difference (final values): 23.49 · 90% CI 5.02 to 41.96
SecondaryPercentage of Participants With DAS28-4 (ESR) ≤3.2

DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity.

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-4 (ESR) ≤3.2
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=34,35,37)20.598.572.70
Month 2 (n=34,36,37)35.2913.898.11
Month 3 (n=34,36,37)32.3530.5613.51
Month 6 (n=34,36,37)41.1827.7818.92
Month 9 (n=34,36,37)44.1233.3318.92
Month 12 (n=34,36,37)50.0030.5616.22
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0160 (2-sided p-value; alpha=0.10) · Mean difference (final values): 17.88 · 90% CI 5.66 to 30.10
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.2798 (2-sided p-value; alpha=0.10) · Mean difference (final values): 5.86 · 90% CI -3.06 to 14.80
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0036 (2-sided p-value; alpha=0.10) · Mean difference (final values): 27.18 · 90% CI 11.81 to 42.55
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.4287 (2-sided p-value; alpha=0.10) · Mean difference (final values): 5.78 · 90% CI -6.23 to 17.79
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0544 (2-sided p-value; alpha=0.10) · Mean difference (final values): 18.83 · 90% CI 2.72 to 34.95
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0732 (2-sided p-value; alpha=0.10) · Mean difference (final values): 17.04 · 90% CI 1.39 to 32.69
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0360 (2-sided p-value; alpha=0.10) · Mean difference (final values): 22.25 · 90% CI 4.79 to 39.72
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.3688 (2-sided p-value; alpha=0.10) · Mean difference (final values): 8.85 · 90% CI -7.35 to 25.07
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0182 (2-sided p-value; alpha=0.10) · Mean difference (final values): 25.19 · 90% CI 7.63 to 42.76
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1558 (2-sided p-value; alpha=0.10) · Mean difference (final values): 14.41 · 90% CI -2.29 to 31.12
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0012 (2-sided p-value; alpha=0.10) · Mean difference (final values): 33.78 · 90% CI 16.51 to 51.05
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.1426 (2-sided p-value; alpha=0.10) · Mean difference (net): 14.33 · 90% CI -1.74 to 30.42
SecondaryPercentage of Participants With DAS28-4 (ESR) <2.6

DAS28-4(ESR) was calculated from swollen joint count and tender joint count using 28 joints count, ESR (mm/hour) and Participant's Global Assessment of Disease Activity (participant rated arthritis activity assessment). Total score range: 0 to 9.4, higher score=more disease activity. DAS28-4(ESR) \<2.6 implied remission.

Time frame:
Months 1, 2, 3, 6, 9, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-4 (ESR) <2.6
percentage of participantsTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Month 1 (n=34,35,37)5.882.860.00
Month 2 (n=34,36,37)17.655.562.70
Month 3 (n=34,36,37)23.532.7813.51
Month 6 (n=34,36,37)29.4113.8913.51
Month 9 (n=34,36,37)35.2913.8916.22
Month 12 (n=34,36,37)32.3519.4413.51
Statistical analysis
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.1449 (2-sided p-value; alpha=0.10) · Mean difference (final values): 5.88 · 90% CI -0.75 to 12.52
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.3102 (2-sided p-value; alpha=0.10) · Mean difference (final values): 2.85 · 90% CI -1.77 to 7.48
  • Tofacitinib (CP-690,550) Plus MTX vs Tofacitinib (CP-690,550) · Normal approximation to the binomial · p = 0.0342 (2-sided p-value; alpha=0.10) · Mean difference (final values): 14.94 · 90% CI 3.32 to 26.55
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.5400 (2-sided p-value; alpha=0.10) · Mean difference (final values): 2.85 · 90% CI -4.80 to 10.51
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.2759 (2-sided p-value; alpha=0.10) · Mean difference (final values): 10.01 · 90% CI -5.10 to 25.13
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.0859 (2-sided p-value; alpha=0.10) · Mean difference (final values): -10.73 · 90% CI -21.02 to -0.45
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0985 (2-sided p-value; alpha=0.10) · Mean difference (final values): 15.89 · 90% CI 0.06 to 31.73
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.9628 (2-sided p-value; alpha=0.10) · Mean difference (final values): 0.37 · 90% CI -12.86 to 13.61
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0612 (2-sided p-value; alpha=0.10) · Mean difference (final values): 19.07 · 90% CI 2.31 to 35.84
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.7807 (2-sided p-value; alpha=0.10) · Mean difference (final values): -2.32 · 90% CI -16.08 to 11.43
  • Tofacitinib (CP-690,550) Plus MTX vs Methotrexate · Normal approximation to the binomial · p = 0.0544 (2-sided p-value; alpha=0.10) · Mean difference (final values): 18.83 · 90% CI 2.72 to 34.95
  • Tofacitinib (CP-690,550) vs Methotrexate · Normal approximation to the binomial · p = 0.4937 (2-sided p-value; alpha=0.10) · Mean difference (final values): 5.93 · 90% CI -8.32 to 20.18

Adverse events

Collected over Adverse events were collected up to 28 calendar days after the last administration of investigational product.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib (CP-690,550) Plus MTX—2/36 (5.6%)24/36 (66.7%)
Tofacitinib (CP-690,550)—1/36 (2.8%)31/36 (86.1%)
Methotrexate—2/37 (5.4%)29/37 (78.4%)
Most frequent serious events
Most frequent serious events
EventTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Angina pectorisCardiac disorders0/361/360/37
Anal abscessInfections and infestations1/360/360/37
Foot deformityMusculoskeletal and connective tissue disorders1/360/360/37
HematocheziaGastrointestinal disorders0/360/361/37
CholelithiasisHepatobiliary disorders0/360/361/37
Most frequent other events
Showing 10 of 130
Most frequent other events
EventTofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)Methotrexate
Alanine aminotransferase increasedInvestigations6/360/365/37
HypertensionVascular disorders1/366/360/37
GastritisGastrointestinal disorders0/365/364/37
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/362/365/37
RashSkin and subcutaneous tissue disorders1/364/360/37
BronchitisInfections and infestations3/360/360/37
PharyngitisInfections and infestations2/363/362/37
Upper respiratory tract infectionInfections and infestations3/362/362/37
Blood creatine phosphokinase increasedInvestigations1/363/361/37
HeadacheNervous system disorders3/362/362/37

Baseline characteristics

Full Analysis Set (FAS): all participants who were randomized to study medication and received at least 1 dose of randomized study medication.

Age, Continuous
Age, Continuous(years)Tofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)MethotrexateTotal
Mean47.8 ± 12.350.8 ± 12.847.8 ± 11.648.8 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib (CP-690,550) Plus MTXTofacitinib (CP-690,550)MethotrexateTotal
Female31302990
Male56819
08

Study locations

40 sites
  • ArthroCare, Arthritis Care & Research, PC
    Gilbert, Arizona 85234, United States
  • Talbert Medical Group
    Huntington Beach, California 92646, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • DMI Research, Inc.
    Pinellas Park, Florida 33782, United States
  • St. Petersburg Arthritis Center
    St. Petersburg, Florida 33710, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104 5005, United States
  • Office of John P. Lavery, MD, PA
    Allen, Texas 75013, United States
  • OMI - Organización Médica de Investigación
    Buenos Aires, C1015ABO, Argentina
  • Saint Dennis Medical Group S.A.
    Buenos Aires, C1034ACO, Argentina
  • Consultorios Reumatologicos Pampa
    Buenos Aires, C1428DZF, Argentina
  • Hospital Base Valdivia
    Valdivia, Region XIV 5090145, Chile
  • Consulta Privada Dr. Juan Ignacio Vargas
    Osorno, X Region 5311089, Chile
  • University Hospital Centre Split,Department for Internal Medicine, Division of Clinical Rheumatology
    Split, 21000, Croatia
  • General Hospital Sveti Duh
    Zagreb, 10000, Croatia
  • ARTMEDI UPD s r.o.
    Hostivice, 253 01, Czech Republic
  • DC Mediscan
    Praha 11 - Chodov, 148 00, Czech Republic
  • Nemocnice na Frantisku s poliklinikou
    Praha 1, 110 00, Czech Republic
  • Nemocnice na Frantisku
    Praha 1, 110 00, Czech Republic
  • Revmatologicky ustav
    Praha 2, 128 50, Czech Republic
  • Uherskohradistska nemocnice, a.s.
    Uherske Hradiste, 686 68, Czech Republic
  • Nemocnice Atlas, a.s.
    Zlin, 760 01, Czech Republic
  • PV-Medical s.r.o.
    Zlin, 760 01, Czech Republic
  • Drug Research Center Kft.
    Balatonfured, 8230, Hungary
  • Orszagos Reumatologiai es Fizioterapias Intezet
    Budapest, 1023, Hungary
  • Synexus Magyarorszag Kft.
    Budapest, 1036, Hungary
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Reumatologiai Tanszek
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz/Reumatologiai es Mozgasszervi Rehabilitacios Centrum
    Gyor, 9027, Hungary
  • Centro de Investigacion y Tratamiento Reumatologico S.C.
    Mexico, D. F. 11850, Mexico
  • Hospital Angeles Mocel
    Mexico, D.f. 11850, Mexico
  • Centro de Investigacion y Tratamiento Reumatologico SC
    Mexico, Distrito Federal 11850, Mexico
  • Hospital Angeles Mocel
    Chapultepec, 11850, Mexico
  • Investigacion y Biomedicina de Chihuahua S.C
    Chihuahua, 31000, Mexico
  • Hospital Angeles Mocel
    Mexico D.F., 11850, Mexico
  • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.
    San Luis Potosi, 78200, Mexico
  • Niepubliczny Zaklad Opieki Zdrowotnej Centrum Osteoporozy i Chorob Kostno-Stawowych J.
    Bialystok, 15-879, Poland
  • Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj
    Poznan, 61-397, Poland
  • Nzoz "Nasz Lekarz"
    Torun, 87-100, Poland
  • Mindful Medical Research
    San Juan, 00918, Puerto Rico
  • San Juan Arthritis & Research Center
    San Juan, 00918, Puerto Rico
09

References and documents

Publications

  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6. PubMed 34870800 ↗
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. PubMed 33127856 ↗
  • van der Heijde D, Landewe RBM, Wollenhaupt J, Strengholt S, Terry K, Kwok K, Wang L, Cohen S. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. Rheumatology (Oxford). 2021 Apr 6;60(4):1708-1716. doi: 10.1093/rheumatology/keaa476. PubMed 33057725 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Conaghan PG, Ostergaard M, Troum O, Bowes MA, Guillard G, Wilkinson B, Xie Z, Andrews J, Stein A, Chapman D, Koenig A. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis Res Ther. 2019 Oct 21;21(1):214. doi: 10.1186/s13075-019-2000-1. PubMed 31639034 ↗
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31. PubMed 28143815 ↗
  • Conaghan PG, Ostergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, Irazoque-Palazuelos F, Soto-Raices O, Hrycaj P, Xie Z, Zhang R, Wyman BT, Bradley JD, Soma K, Wilkinson B. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016 Jun;75(6):1024-33. doi: 10.1136/annrheumdis-2015-208267. Epub 2016 Jan 25. PubMed 27002108 ↗
  • Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779. PubMed 25047021 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2010
First posted
Jul 16, 2010
Start
Oct 2010
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Apr 22, 2015
Last update
Apr 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01164579
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 16, 2010
Start date
Oct 2010
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Apr 22, 2015
Last update
Apr 22, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tofacitinib · Methotrexate

Start the discussion